- Home
- MESO vs DFH Comparison
MESO vs DFH Comparison
Compare MESO & DFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- DFH
- Stock Information
- Founded
- MESO 2004
- DFH 2008
- Country
- MESO Australia
- DFH United States
- Employees
- MESO N/A
- DFH N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- DFH Homebuilding
- Sector
- MESO Health Care
- DFH Consumer Discretionary
- Exchange
- MESO Nasdaq
- DFH Nasdaq
- Market Cap
- MESO 2.0B
- DFH 2.2B
- IPO Year
- MESO N/A
- DFH 2021
- Fundamental
- Price
- MESO $18.04
- DFH $24.29
- Analyst Decision
- MESO Buy
- DFH Hold
- Analyst Count
- MESO 4
- DFH 1
- Target Price
- MESO $13.50
- DFH $38.00
- AVG Volume (30 Days)
- MESO 828.2K
- DFH 698.8K
- Earning Date
- MESO 02-28-2025
- DFH 02-27-2025
- Dividend Yield
- MESO N/A
- DFH N/A
- EPS Growth
- MESO N/A
- DFH 15.80
- EPS
- MESO N/A
- DFH 3.03
- Revenue
- MESO $5,902,000.00
- DFH $4,028,851,000.00
- Revenue This Year
- MESO $65.99
- DFH $15.56
- Revenue Next Year
- MESO $425.77
- DFH N/A
- P/E Ratio
- MESO N/A
- DFH $8.02
- Revenue Growth
- MESO N/A
- DFH 8.59
- 52 Week Low
- MESO $1.72
- DFH $21.42
- 52 Week High
- MESO $22.00
- DFH $44.38
- Technical
- Relative Strength Index (RSI)
- MESO 59.20
- DFH 45.16
- Support Level
- MESO $15.92
- DFH $23.34
- Resistance Level
- MESO $17.67
- DFH $25.54
- Average True Range (ATR)
- MESO 1.38
- DFH 0.97
- MACD
- MESO -0.37
- DFH 0.45
- Stochastic Oscillator
- MESO 37.14
- DFH 69.66
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About DFH Dream Finders Homes Inc.
Dream Finders Homes Inc is engaged in the home building business. It designs, builds, and sells homes in Jacksonville, Orlando, Denver, the Washington D.C. metropolitan area, and Austin. The company operates through six geographical divisions namely, Jacksonville, Orlando, Denver, Washington DC (Capital), and the Carolinas (H&H Homes), Jet Home Loans LLC. Jacksonville division generates majority of the revenue for the firm.